A Phase 3 interventional study of olanzapine in Bipolar Disorder I or II, sponsored by Eli Lilly and Company. Completed at 16 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-06-24.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing olanzapine in Bipolar Disorder — none open to participants now, none under way, none of them phase 3. Olanzapine · Bipolar Disorder.
Among the 28 studies testing olanzapine in Bipolar Disorder, this one is the 11th largest by enrollment, is one of 4 that started in 2005, is one of 7 in phase 3, and was the 16th registered.
1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.
Browse Bipolar Disorder studies →None of the 28 studies testing olanzapine in Bipolar Disorder is open now. The open studies under Bipolar Disorder, anywhere →
Olanzapine: first FDA approval 1996 (ZYPREXA), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 4 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 141 is above the median of 64 across 1,280 interventional studies indexed under Bipolar Disorder.
Median enrollment 120 across the 28 interventional studies. Of the 27 that completed or were terminated, 8 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 28 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
20 studies in Bipolar Disorder by Eli Lilly and Company: 1 open now, 1 under way, none of them phase 3. Of 19 finished, 5 (26%) have results posted.
Among the 20 studies in Bipolar Disorder by Eli Lilly and Company, this one is the 11th largest by enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2005, is one of 5 in phase 3, and was the 10th registered.
Eli Lilly and Company’s Bipolar Disorder studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing olanzapine in Bipolar Disorder, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 20 in Bipolar Disorder:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A non randomized study to validate the MATHYS Scale in a population of in and outpatients greater than or equal to 18 years of age, suffering from Bipolar Disorder I or II, and treated with olanzapine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must meet , Fourth Edition, Text Revision (DSM-IV-TR) disease diagnostic criteria for Bipolar Disorder
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: olanzapine
5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks.
Also known as: LY170053, Velotab, Zydis
Mean Changes From Baseline to 6 Week and 24 Week Endpoints in the Multidimensional Assessment of THYmic States Scale (MATHYS) Total Score
A visual analogic scale consisting of 20 items. Item scores vary from 0 (inhibition of the state evaluated by the item) to 10 (excitation for the evaluated state), except for items 5 to 10 and 17 and 18 which are inversed and are consequently to be reversed before the analysis. Total score is sum of the 20 items and can vary from 0 to 200.
Time frame: Baseline, 6 Weeks, 24 weeks
Baseline MATHYS Assessment - Principal Component Analysis and Orthogonal Transformation Matrix
This analysis indicates whether the total score is correct and provides enough information, or if subscores need to be calculated. Eigen value, proportion and cumulative are statistical parameters from the Principal Component Analysis, given for each factor.
Time frame: Baseline
Mean Change From Baseline to 6 Week and 24 Week Endpoints in the Hamilton 17-Items Depression Scale (HAMD-17) Total Score
The 17-item HAMD measures depression severity. Each item was evaluated and scored using either a 5-point scale (e.g. absent, mild, moderate, severe, very severe) or a 3-point scale (e.g. absent, mild, marked). The total score of HAMD-17 may range from 0 (not at all depressed) to 52 (severely depressed).
Time frame: Baseline, 6 Weeks, 24 Weeks
Mean Change From Baseline to 6 Week and 24 Week Endpoints in the Hamilton Anxiety Scale (HAMA) Total Score
The 14-item HAMA assesses the severity of anxiety. The investigator talked to the patient about their symptoms over the previous week before the study visit. Each item was scored using a 5-point scale, i.e. 0 = absent to 4 = severe. The total score of HAMA-14 may range from 0 (not present) to 56 (very severe).
Time frame: Baseline, 6 Weeks, 24 Weeks
Mean Change From Baseline to 6 Week and 24 Week Endpoints in the Young Mania Rating Scale (YMRS) Total Score
The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.
Time frame: Baseline, 6 Weeks, 24 Weeks
Mean Change From Baseline to 24 Week Endpoint in Glycaemia Levels (Glucose Fasting Levels)
Time frame: baseline and 24 weeks
Increases and Decreases in Fasting Glucose Levels
Time frame: over 24 weeks
Mean Change From Baseline to 24 Week Endpoint in Lipids
Baseline, change from baseline, and percent change for the following lipids are presented: Total Cholesterol (TC), High Density Lipoproteins (HDL), Low Density Lipoproteins (LDL), and Triglycerides (TG).
Time frame: Baseline and 24 Weeks
Increases and Decreases in Lipid Levels
Time frame: over 24 weeks
Mean Change From Baseline to 24 Week Endpoint in Weight
Time frame: Baseline and 24 weeks
Weight Gain Compared to Baseline
Weight gain at anytime more than 7%-15% or 25% of body weight compared to baseline
Time frame: over 24 weeks
Wellness Interventional Program for Weight Gain Management in Patients (for Those Who Gain at Anytime More Than 7% of Body Weight, Compared to Baseline)
Time frame: 24 weeks
MATHYS Total Score at Baseline - According to Thymic Reactivity Assessment
A visual analogic scale consisting of 20 items. Items scores vary from 0 (inhibition of the state evaluated by the item) to 10 (excitation for the evaluated state), except for items 5 to 10 and 17 and 18, which are inversed and are consequently to be reversed before the analysis. Total score is sum of the 20 items and can vary from 0 to 200.
Time frame: Baseline
Change From Baseline to 6 Week and 24 Week Endpoints in HAMA Total Scores - According to Thymic Reactivity Assessment
The 14-item HAMA assesses the severity of anxiety. The investigator talked to the patient about their symptoms over the previous week before the study visit. Each item was scored using a 5-point scale, i.e. 0 = absent to 4 = severe. The total score of HAMA-14 may range from 0 (not present) to 56 (very severe).
Time frame: Baseline, 6 Weeks, 24 Weeks
Change From Baseline to 6 Week and 24 Week Endpoints in HAMD-17 Total Scores - According to Thymic Reactivity Assessment
The 17-item HAMD measures depression severity. Each item was evaluated and scored using either a 5-point scale (e.g. absent, mild, moderate, severe, very severe) or a 3-point scale (e.g. absent, mild, marked). The total score of HAMD-17 may range from 0 (not at all depressed) to 52 (severely depressed).
Time frame: Baseline, 6 Weeks, 24 Weeks
Change From Baseline to 6 Week and 24 Week Endpoints in YMRS Total Scores - According to Thymic Reactivity Assessment
The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.
Time frame: Baseline, 6 Weeks, 24 Weeks
Emotional Reactivity With the Physiological Measure of Heart Rate
to assess emotional reactivity with the physiological measure of heart rate, recorded as a function of slides sessions from the International Affective Picture System, in a defined subgroup of patients
Time frame: 12 weeks
Emotional Reactivity With the Physiological Measure of Skin Conductance
To assess emotional reactivity with the physiological measure of skin conductance, recorded as a function of slides sessions from the International Affective Picture System, in a defined subgroup of patients.
Time frame: 12 weeks
Emotional Reactivity With the Physiological Measure of Startle Reflex Response - Latency of Blink
To assess emotional reactivity with the physiological measure of startle reflex response by measuring the latency of the blink, recorded as a function of slides sessions from the International Affective Picture System, in a defined subgroup of patients.
Time frame: 12 weeks
Emotional Reactivity With the Physiological Measure of Startle Reflex Response - Amplitude of Blink
To assess emotional reactivity with the physiological measure of startle reflex response - by measuring the amplitude of the blink, recorded as a function of slides sessions from the International Affective Picture System, in a defined subgroup of patients.
Time frame: 12 weeks
| Milestone | Manic Episode | Hypomanic Episode | Mixed Episode | Depressive Episode |
|---|---|---|---|---|
| Started | 36 | 31 | 26 | 48 |
| Completed | 21 | 24 | 21 | 27 |
| Not completed | 15 | 7 | 5 | 21 |
| Withdrew: Adverse event | 2 | 1 | 0 | 3 |
| Withdrew: Lack of efficacy | 5 | 1 | 2 | 6 |
| Withdrew: Physician decision | 1 | 2 | 1 | 3 |
| Withdrew: Protocol violation | 2 | 0 | 0 | 1 |
| Withdrew: Sponsor decision | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 2 | 2 | 7 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 1 |
A visual analogic scale consisting of 20 items. Item scores vary from 0 (inhibition of the state evaluated by the item) to 10 (excitation for the evaluated state), except for items 5 to 10 and 17 and 18 which are inversed and are consequently to be reversed before the analysis. Total score is sum of the 20 items and can vary from 0 to 200.
| units on a scale | Manic Episode | Hypomanic Episode | Mixed Episode | Depressive Episode |
|---|---|---|---|---|
| Baseline (n=34, 31, 25, 48) | 140.55 ± 22.18 | 136.52 ± 22.45 | 116.74 ± 21.30 | 76.88 ± 22.91 |
| 6 Week Endpoint (n=31, 31, 25, 44) | 115.37 ± 23.09 | 105.15 ± 23.10 | 101.58 ± 22.55 | 93.41 ± 23.71 |
| Change from 6 Week Endpoint (n=30, 31, 24, 44) | -22.91 ± 28.70 | -31.37 ± 30.46 | -13.32 ± 26.37 | 17.17 ± 26.62 |
| 24 Week Endpoint (n=35, 31, 26, 47) | 115.15 ± 24.84 | 103.16 ± 23.03 | 91.56 ± 25.19 | 94.58 ± 27.09 |
| Change from 24 Week Endpoint (n=34, 31, 25, 47) | -24.67 ± 24.83 | -33.36 ± 33.61 | -26.08 ± 40.51 | 17.04 ± 31.81 |
The 17-item HAMD measures depression severity. Each item was evaluated and scored using either a 5-point scale (e.g. absent, mild, moderate, severe, very severe) or a 3-point scale (e.g. absent, mild, marked). The total score of HAMD-17 may range from 0 (not at all depressed) to 52 (severely depressed).
| units on a scale | Manic Episode | Hypomanic Episode | Mixed Episode | Depressive Episode |
|---|---|---|---|---|
| Baseline (n=35, 30, 26, 48) | 6.46 ± 4.86 | 8.43 ± 5.33 | 12.65 ± 4.83 | 16.06 ± 7.19 |
| Change from 6 Week Endpoint (n=29, 29, 25, 45) | -1.79 ± 4.59 | -3.10 ± 4.59 | -5.60 ± 6.60 | -8.51 ± 6.22 |
| Change from 24 Week Endpoint (n=34, 30, 26, 47) | -1.74 ± 5.02 | -3.20 ± 6.40 | -5.50 ± 6.72 | -7.96 ± 7.18 |
The 14-item HAMA assesses the severity of anxiety. The investigator talked to the patient about their symptoms over the previous week before the study visit. Each item was scored using a 5-point scale, i.e. 0 = absent to 4 = severe. The total score of HAMA-14 may range from 0 (not present) to 56 (very severe).
| units on a scale | Manic Episode | Hypomanic Episode | Mixed Episode | Depressive Episode |
|---|---|---|---|---|
| Baseline (n=36, 31, 26, 48) | 7.78 ± 6.29 | 11.94 ± 7.73 | 15.46 ± 7.17 | 15.08 ± 7.35 |
| Change from 6 Week Endpoint (n=31, 31, 25, 45) | -2.68 ± 4.85 | -5.48 ± 5.89 | -7.32 ± 6.31 | -6.76 ± 6.61 |
| Change from 24 Week Endpoint (n=35, 31, 26, 47) | -2.26 ± 4.80 | -5.65 ± 7.36 | -7.62 ± 7.87 | -6.83 ± 7.19 |
The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.
| units on a scale | Manic Episode | Hypomanic Episode | Mixed Episode | Depressive Episode |
|---|---|---|---|---|
| Baseline (n=36, 31, 25, 46) | 24.50 ± 10.34 | 17.84 ± 4.88 | 12.96 ± 7.69 | 2.78 ± 3.64 |
| Change from 6 Week Endpoint (n=31, 31, 24, 43) | -13.65 ± 9.38 | -13.13 ± 6.02 | -9.67 ± 7.91 | -0.86 ± 3.54 |
| Change from 24 Week Endpoint (n=35, 31, 25, 45) | -14.00 ± 10.94 | -14.45 ± 7.36 | -10.60 ± 7.95 | -0.82 ± 3.24 |
| milligrams per deciliter | Manic Episode | Hypomanic Episode | Mixed Episode | Depressive Episode |
|---|---|---|---|---|
| Baseline (n=33, 30, 23, 47) | 89.27 ± 16.31 | 85.99 ± 11.33 | 85.94 ± 12.58 | 88.52 ± 13.95 |
| Change from 24 Week Endpoint (n=26, 28, 23, 40) | -3.07 ± 16.15 | 4.65 ± 15.32 | 3.89 ± 9.62 | 7.31 ± 30.42 |
| participants | Manic Episode | Hypomanic Episode | Mixed Episode | Depressive Episode |
|---|---|---|---|---|
| At Least One Increase in Fasting Glucose (FG) | 5 | 9 | 3 | 10 |
| At Least One Decrease in FG | 4 | 8 | 1 | 11 |
| At Least One Increase/Decrease in FG | 7 | 10 | 3 | 15 |
| Patients Who Increase and Decrease During Study | 2 | 7 | 1 | 6 |
Baseline, change from baseline, and percent change for the following lipids are presented: Total Cholesterol (TC), High Density Lipoproteins (HDL), Low Density Lipoproteins (LDL), and Triglycerides (TG).
| milligrams per deciliter | Manic Episode | Hypomanic Episode | Mixed Episode | Depressive Episode |
|---|---|---|---|---|
| TC Baseline (n=33, 30, 24, 46) | 182.88 ± 41.88 | 191.55 ± 42.49 | 210.51 ± 50.78 | 203.77 ± 44.66 |
| Change in TC from 24 Week Endpoint (n=26,28,23,41) | 23.64 ± 33.95 | 2.26 ± 27.25 | 7.03 ± 30.77 | 4.41 ± 50.69 |
| Percent Change in TC (n=26, 28, 23, 41) | 14.96 ± 19.57 | 3.10 ± 13.83 | 4.41 ± 16.97 | 4.68 ± 23.67 |
| HDL Baseline (n=33, 30, 23, 46) | 50.21 ± 14.65 | 56.87 ± 16.77 | 57.46 ± 19.13 | 50.78 ± 13.35 |
| Change in HDL from Endpoint (n=26, 28, 22, 41) | 1.24 ± 13.32 | 1.57 ± 13.14 | -0.45 ± 16.27 | 3.25 ± 12.72 |
| Percent Change in HDL (n=26, 28, 22, 41) | 6.04 ± 26.43 | 6.17 ± 26.06 | 3.78 ± 26.12 | 8.87 ± 23.97 |
| LDL Baseline (n=34, 30, 23, 46) | 112.76 ± 39.81 | 112.16 ± 31.37 | 129.70 ± 44.64 | 128.81 ± 39.26 |
| Change in LDL from Endpoint (n=27, 27, 22, 41) | 14.22 ± 41.05 | 1.28 ± 36.64 | 9.46 ± 32.04 | -1.19 ± 42.24 |
| Percent Change in LDL (n=27, 27, 22, 41) | 20.54 ± 33.94 | 5.15 ± 33.05 | 11.37 ± 28.57 | 3.41 ± 32.28 |
| TG Baseline (n=35, 30, 23, 46) | 115.81 ± 43.15 | 110.66 ± 89.64 | 131.37 ± 71.65 | 120.15 ± 66.63 |
| Change in TG from 24 Week Endpoint (n=27,28,22,41) | 8.37 ± 66.50 | 25.86 ± 90.32 | -1.16 ± 49.06 | 13.85 ± 67.59 |
| Percent Change in TG (n=27, 28, 22, 41) | 20.65 ± 72.42 | 40.06 ± 74.56 | 4.10 ± 36.59 | 25.95 ± 60.73 |
| participants | Manic Episode | Hypomanic Episode | Mixed Episode | Depressive Episode |
|---|---|---|---|---|
| At Least One Increase for Total Cholesterol (TC) | 18 | 7 | 11 | 20 |
| At Least One Decrease for TC | 11 | 9 | 10 | 16 |
| At Least One Increase/Decrease for TC | 19 | 12 | 14 | 26 |
| Patients Who Increase & Decrease in TC | 10 | 4 | 7 | 10 |
| ≥1 Increase for High Density Lipoprotein (HDL) | 8 | 5 | 6 | 11 |
| At Least One Decrease for HDL | 4 | 6 | 5 | 8 |
| At Least One Increase/Decrease for HDL | 9 | 8 | 7 | 12 |
| Patients Who Increase & Decrease in HDL | 3 | 3 | 4 | 7 |
| ≥1 Increase for Low Density Lipoprotein (LDL) | 15 | 8 | 11 | 17 |
| At Least One Decrease for LDL | 8 | 7 | 7 | 17 |
| At Least One Increase/Decrease for LDL | 17 | 12 | 12 | 25 |
| Patients Who Increase & Decrease in LDL | 6 | 3 | 6 | 9 |
| At Least One Increase for Triglycerides (TG) | 11 | 7 | 6 | 11 |
| At Least One Decrease for TG | 12 | 7 | 7 | 13 |
| At Least One Increase/Decrease for TG | 15 | 11 | 8 | 16 |
| Patients Who Increase & Decrease in TG | 8 | 3 | 5 | 8 |
| kilograms | Manic Episode | Hypomanic Episode | Mixed Episode | Depressive Episode |
|---|---|---|---|---|
| Mean Change From Baseline to 24 Week Endpoint in Weight | 1.37 ± 2.98 | 1.91 ± 3.44 | 1.78 ± 4.43 | 2.15 ± 2.60 |
Weight gain at anytime more than 7%-15% or 25% of body weight compared to baseline
| participants | Manic Episode | Hypomanic Episode | Mixed Episode | Depressive Episode |
|---|---|---|---|---|
| No Significant Gain | 30 ± 2.98 | 26 ± 3.44 | 18 ± 4.43 | 42 ± 2.60 |
| >25% | 0 | 0 | 0 | 0 |
| >15% | 1 | 2 | 1 | 0 |
| >7% | 5 | 3 | 7 | 5 |
| Missing Data | 0 | 0 | 0 | 1 |
| participants | Weight Gain Subgroup |
|---|---|
| Advised to Consult Dietician - No | 8 |
| Advised to Consult Dietician - Yes | 16 |
| Performed a Wellness Program - No | 6 |
| Performed a Wellness Program - Yes | 10 |
| Number of Wellnes Program Consults - 1 | 5 |
| Number of Wellnes Program Consults - 2 | 2 |
| Number of Wellnes Program Consults - 3 | 3 |
| Patients Losing Weight After Consultation | 8 |
| Patients Gaining Weight After Consultation | 8 |
| Patients with Stable Weight After Consultation | 0 |
A visual analogic scale consisting of 20 items. Items scores vary from 0 (inhibition of the state evaluated by the item) to 10 (excitation for the evaluated state), except for items 5 to 10 and 17 and 18, which are inversed and are consequently to be reversed before the analysis. Total score is sum of the 20 items and can vary from 0 to 200.
| units on a scale | Thymic Hypo-Reactive | Thymic Hyper-Reactivity | Neither |
|---|---|---|---|
| MATHYS Total Score at Baseline - According to Thymic Reactivity Assessment | 81.24 ± 30.81 | 122.49 ± 32.01 | 117.26 ± 26.41 |
The 14-item HAMA assesses the severity of anxiety. The investigator talked to the patient about their symptoms over the previous week before the study visit. Each item was scored using a 5-point scale, i.e. 0 = absent to 4 = severe. The total score of HAMA-14 may range from 0 (not present) to 56 (very severe).
| units on a scale | Thymic Hypo-Reactivity | Thymic Hyper-Reactivity | Neither |
|---|---|---|---|
| Baseline (n=30, 101, 10) | 12.87 ± 7.09 | 12.63 ± 7.95 | 11.40 ± 7.95 |
| Change from 6 Week Endpoint (n=29, 93, 10) | -4.93 ± 5.62 | -5.96 ± 6.56 | -4.30 ± 3.95 |
| Change from 24 Week Endpoint (n=30, 99, 10) | -4.83 ± 5.94 | -5.65 ± 7.39 | -6.90 ± 7.43 |
The 17-item HAMD measures depression severity. Each item was evaluated and scored using either a 5-point scale (e.g. absent, mild, moderate, severe, very severe) or a 3-point scale (e.g. absent, mild, marked). The total score of HAMD-17 may range from 0 (not at all depressed) to 52 (severely depressed).
| units on a scale | Thymic Hypo-Reactivity | Thymic Hyper-Reactivity | Neither |
|---|---|---|---|
| Baseline (n=29, 100, 10) | 14.48 ± 7.02 | 10.64 ± 6.85 | 9.50 ± 7.01 |
| Change from 6 Week Endpoint (n=28, 90, 10) | -6.61 ± 5.02 | -4.89 ± 6.62 | -4.00 ± 5.12 |
| Change from 24 Week Endpoint (n=28, 98, 10) | -6.48 ± 4.32 | -4.55 ± 7.58 | -3.80 ± 4.85 |
The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.
| units on a scale | Thymic Hypo-Reactivity | Thymic Hyper-Reactivity | Neither |
|---|---|---|---|
| Baseline (n=27, 101, 10) | 4.48 ± 7.99 | 16.50 ± 10.65 | 10.00 ± 7.24 |
| Change from 6 Week Endpoint (n=26, 93, 10) | -2.38 ± 7.90 | -10.45 ± 8.46 | -6.50 ± 4.70 |
| Change from 24 Week Endpoint (n=27, 99, 10) | -1.70 ± 5.19 | -11.29 ± 9.89 | -7.60 ± 5.52 |
to assess emotional reactivity with the physiological measure of heart rate, recorded as a function of slides sessions from the International Affective Picture System, in a defined subgroup of patients
No measurements were reported for this outcome.
To assess emotional reactivity with the physiological measure of skin conductance, recorded as a function of slides sessions from the International Affective Picture System, in a defined subgroup of patients.
No measurements were reported for this outcome.
To assess emotional reactivity with the physiological measure of startle reflex response by measuring the latency of the blink, recorded as a function of slides sessions from the International Affective Picture System, in a defined subgroup of patients.
No measurements were reported for this outcome.
To assess emotional reactivity with the physiological measure of startle reflex response - by measuring the amplitude of the blink, recorded as a function of slides sessions from the International Affective Picture System, in a defined subgroup of patients.
No measurements were reported for this outcome.
This analysis indicates whether the total score is correct and provides enough information, or if subscores need to be calculated. Eigen value, proportion and cumulative are statistical parameters from the Principal Component Analysis, given for each factor.
| value | Eigen Value | Proportion | Cumulative |
|---|---|---|---|
| Factor 1 | 8.77 | 0.4383 | 0.4383 |
| Factor 2 | 2.01 | 0.1006 | 0.5389 |
| Factor 3 | 1.19 | 0.0594 | 0.5984 |
| Factor 4 | 1.042 | 0.0521 | 0.6505 |
| Factor 5 | 0.98 | 0.0490 | 0.6995 |
| Factor 6 | 0.79 | 0.0397 | 0.7392 |
| Factor 7 | 0.69 | 0.0347 | 0.7739 |
| Factor 8 | 0.64 | 0.0322 | 0.8061 |
| Factor 9 | 0.56 | 0.0280 | 0.8341 |
| Factor 10 | 0.54 | 0.0268 | 0.8608 |
| Factor 11 | 0.45 | 0.0227 | 0.8836 |
| Factor 12 | 0.44 | 0.0219 | 0.9055 |
| Factor 13 | 0.37 | 0.0186 | 0.9241 |
| Factor 14 | 0.34 | 0.0171 | 0.9412 |
| Factor 15 | 0.28 | 0.0139 | 0.9551 |
| Factor 16 | 0.26 | 0.0131 | 0.9682 |
| Factor 17 | 0.20 | 0.0100 | 0.9782 |
| Factor 18 | 0.18 | 0.0091 | 0.9873 |
| Factor 19 | 0.14 | 0.0071 | 0.9944 |
| Factor 20 | 0.11 | 0.0056 | 1.0000 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Olanzapine | — | — | — |
| Event | Olanzapine |
|---|---|
| Bipolar I disorderPsychiatric disorders | 5/141 |
| DepressionPsychiatric disorders | 4/141 |
| Gastric ulcerGastrointestinal disorders | 1/141 |
| CholecystitisHepatobiliary disorders | 1/141 |
| Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/141 |
| AlcoholismPsychiatric disorders | 1/141 |
| AnxietyPsychiatric disorders | 1/141 |
| Suicide attemptPsychiatric disorders | 1/141 |
| ArteritisVascular disorders | 1/141 |
| Event | Olanzapine |
|---|---|
| Dry mouthGastrointestinal disorders | 8/141 |
| ConstipationGastrointestinal disorders | 7/141 |
| SomnolenceNervous system disorders | 7/141 |
| TremorNervous system disorders | 7/141 |
| AstheniaGeneral disorders | 3/141 |
| Weight increasedInvestigations | 3/141 |
| Vision blurredEye disorders | 2/141 |
| DiarrhoeaGastrointestinal disorders | 2/141 |
| VomitingGastrointestinal disorders | 2/141 |
| Gamma-glutamyltransferase increasedInvestigations | 2/141 |
| Age Continuous(years) | Manic Episode | Hypomanic Episode | Mixed Episode | Depressive Episode | Total |
|---|---|---|---|---|---|
| Mean | 46.39 ± 15.32 | 45.81 ± 11.68 | 46.62 ± 12.87 | 44.35 ± 11.98 | 45.61 ± 12.91 |
| Sex: Female, Male(Participants) | Manic Episode | Hypomanic Episode | Mixed Episode | Depressive Episode | Total |
|---|---|---|---|---|---|
| Female | 19 | 21 | 15 | 25 | 80 |
| Male | 17 | 10 | 11 | 23 | 61 |
| Region of Enrollment(participants) | Manic Episode | Hypomanic Episode | Mixed Episode | Depressive Episode | Total |
|---|---|---|---|---|---|
| France | 36 | 31 | 26 | 48 | 141 |
| Diagnostic Summary(participants) | Manic Episode | Hypomanic Episode | Mixed Episode | Depressive Episode | Total |
|---|---|---|---|---|---|
| Bipolar Disorder I | 36 | 14 | 26 | 31 | 107 |
| Bipolar Disorder II - Hypomanic | 0 | 17 | 1 | 0 | 18 |
| Bipolar Disorder II - Depressed | 0 | 0 | 1 | 17 | 18 |
| Number of Lifetime Suicide Attempts(participants) | Manic Episode | Hypomanic Episode | Mixed Episode | Depressive Episode | Total |
|---|---|---|---|---|---|
| Missing Data | 2 | 3 | 1 | 2 | 8 |
| 0 | 24 | 23 | 15 | 28 | 90 |
| 1 | 8 | 3 | 6 | 5 | 22 |
| 2 | 2 | 0 | 3 | 8 | 13 |
| 4 | 0 | 1 | 0 | 2 | 3 |
| 5 | 0 | 0 | 0 | 2 | 2 |
| 6 | 0 | 1 | 0 | 0 | 1 |
| 10 | 0 | 0 | 1 | 1 | 2 |
| Participants with at Least One Episode of Depression(participants) | Manic Episode | Hypomanic Episode | Mixed Episode | Depressive Episode | Total |
|---|---|---|---|---|---|
| Missing Data | 0 | 0 | 1 | 0 | 1 |
| No | 6 | 2 | 4 | 0 | 12 |
| Yes | 30 | 29 | 21 | 48 | 128 |
| Participants with at Least One Episode of Hypomania(participants) | Manic Episode | Hypomanic Episode | Mixed Episode | Depressive Episode | Total |
|---|---|---|---|---|---|
| Missing Data | 2 | 0 | 3 | 1 | 6 |
| No | 30 | 1 | 14 | 25 | 70 |
| Yes | 4 | 30 | 9 | 22 | 65 |
| Participants with at Least One Episode of Mania(participants) | Manic Episode | Hypomanic Episode | Mixed Episode | Depressive Episode | Total |
|---|---|---|---|---|---|
| Missing Data | 0 | 3 | 1 | 0 | 4 |
| No | 0 | 14 | 11 | 23 | 48 |
| Yes | 36 | 14 | 14 | 25 | 89 |
10 further baseline measures are reported on the registry.
The record gives a start of Nov 2005, a primary completion of May 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2009, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olanzapine